REG - Sunplus Technology - Half-year Report

Sunplus Technology CoAnnouncement

14/08/2020 07:50

RNS Number : 1675W
  
Sunplus Technology Co Limited
  
14 August 2020
  
 

Sunplus Technology Company Limited
Consolidated Balance Sheets
Ended June 30, 2020*
(In Thousands of New Taiwan Dollars)
 



Assets


Amount


Liabilities & Shareholders Equity


Amount




Cash & Equivalent


2,522,714


Current Liabilities


1,871,842




Financial assets at fair value through profit or loss-current  


1,134,670


Non-Current Liabilities


578,935




Accounts & Notes receivable


1,059,175


Total Liabilities


2,450,777




Other Receivable


41,305


Equity attributable to owners of the parent








Inventories


1,019,325


Capital stock


5,919,949




Other current assets


381,322


Shares to be issued 








Total Current Assets


6,158,511


Capital surplus


417,520












Appropriated as legal reserve


1,712,390




Financial assets at fair value through profit or loss - non-current


1,049,555


Appropriated as special reserve


276,189




Financial assets at fair value through other comprehensive income - non-current


198,976


Unappropriated earnings (deficit)


(80,281)




Investments accounted for using the equity method


678,788


Others


(312,264)




Property, plant and equipment


1,952,165


Treasury Stock


(63,401)




Right-of-use asset


235,307


Total equity attributable to owners of the parent


7,870,102




Investment properties


1,007,901












Intangible Assets-Net


187,451


Non-Controlling Interests


1,354,091




Deferred tax assets


29,961


Total Shareholders¡¦ Equity


9,224,193




Net defined benefit asset, non-current


1,163












Other Non-Current Assets


175,192












Total Non-Current Assets


5,516,459












Total Assets


        11,674,970


Total Liabilities & Shareholders' Equity


11,674,970







 
Sunplus Technology Company Limited
Consolidated Statements of Income
From January 1 to June 30, 2020 and 2019
(In Thousands of New Taiwan Dollars, Except Earnings per share) 



Unit: NT$K, Except EPS


2020


2019


YoY




Net sales


2,572,029


2,711,351


(5.14)




Cost


1,398,294


1,561,135


(10.43)




Gross Profit


1,173,735


1,150,216


2.04




  Marketing Expense


152,784


137,333


11.25




  General& Administrative Expense


225,079


247,929


(9.22)




R&D Expenses


743,432


736,339


0.96




Expected credit loss


18


211


(91.47)




Other operating income(Expense)


(104)


143


(172.72)




Total operating income (expense)


52,318


28,547


83.27




Total non-operating income (expense)


21,012


96,495


(78.22)




Income(loss) before income tax from continued operating units


73,330


125,042


(41.36)




Income tax expense


58,031


25,560


127.04




Consolidated Net Income(loss)


15,299


99,482


(84.62)




Consolidated Net Income(loss)

Attributable To Shareholders of the parent


(78,926)


13,332


(692.00)




Consolidated Earnings Per Share NT$ Attributable To Shareholders of the parent*


(0.13)


0.02







* Based on outstanding 588,434,923 shares on 2020/06/30




Sunplus Technology Company Limited
Consolidated Cash Flow Summary
From January 1 toJune 30, 2020 and 2019
(In Thousand New Taiwan Dollars)
 



ITEM


2020


2019




Cash Flow in (out) from operating


(115,677)


183,082




Cash Flow in (out) from Investing


(423,741)


(294,625)




Cash Flow in (out) from Financing


43,807


(150,169)




Impact from Fx Change


(2,303)


3,765




Net Increase (Decrease) in Cash & Cash Equivalents


(497,914)


(257,947)




Cash & Cash Equivalents, Beginning of Period


3,020,628


3,235,721




Cash & Cash Equivalents, End of Period


2,522,714


2,977,774



 
 




Spokesman
Wayne Shen
Tel: +886-3-5786005 ext. 2350
E-mail: wayne@sunplus.com
 


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
IR FIFSRTEISLII